![SonomaEye-full-color-vector[2].png](https://static.wixstatic.com/media/bed00b_da20b9cc704044b0b048ac8ef9190470~mv2_d_3024_2195_s_2.png/v1/fill/w_177,h_123,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/SonomaEye-full-color-vector%5B2%5D.png)
Thank you for your submission!
Pharmacologic techniques for the management of proliferative vitreoretinopathy
Charles DeBoer, MD, PhD
Presenter:
Charles DeBoer, MD, PhD
Authors:
Affiliation:
Byers Eye Institute, Stanford
Purpose: Proliferative vitreoretinopathy is one of the leading causes of failure of primary vitrectomy affecting 5-10% of post-vitrectomy patients. This talk provides current management techniques for proliferative vitreoretinopathy. Various pharmacologic techniques have been evaluated, including intravitreal methotrexate, oral isotretinoin, and oral colchicine.
Methods: Presentation of current relevant studies.
Results: Management strategies and prior results are reviewed for select pharmacologic therapies for proliferative vitreoretinopathy. The focus of this work is the evaluation of current clinical trial data for the use of methotrexate infusion during surgery and intravitreal methotrexate in the post-operative period. Further discussion regarding oral medications for proliferative vitreoretinopathy are discussed, including oral isotretinoin.
Conclusions: This talk discusses current therapeutic strategies for proliferative vitreoretinopathy.